Diabetes Mellitus and Cardiovascular Disease

  • David S. Frankel
  • Peter W. F. Wilson
  • James B. Meigs


Diabetes mellitus is a complex, multifactorial disorder that has an overall prevalence of about 8% in the United States. Whereas approximately 90% of people with diabetes have noninsulin-dependent or type 2 diabetes mellitus (T2DM), the remainder have insulin-dependent or type 1 diabetes mellitus (T1DM). The prevalence of diabetes varies greatly among different ethnic groups. Among Americans older than 20 years of age, the prevalence of diabetes is 8.7% among non-Hispanic whites, 9.5% among Hispanic and Latino Americans, 13.3% among non-Hispanic blacks, and 15.1% among American Indian and Alaskan natives. These wide variations in prevalence are accounted for mainly by T2DM. Although the cause or causes of T2DM are not known, the environment is clearly important. The molecular basis for T1DM is better defined, but the primary cause remains unclear. Despite the etiologic and pathogenic differences between T2DM and T1DM, the chronic sequelae of both forms of diabetes are the same; cardiovascular disease, particularly coronary heart disease (CHD), is the major cause of morbidity and mortality in diabetic patients. In fact, CHD causes greater than 75% of deaths among those with diabetes and shortens life expectancy by 10 years [1].


Coronary Heart Disease Diabetic Patient Glucose Control Blood Glucose Control Shorten Life Expectancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    A merican Diabetes Association: National Diabetes Fact Sheet. Alexandria, VA: American Diabetes Association; 2005.Google Scholar
  2. 2.
    Diagnosis and classification of diabetes mellitus: Diabetes Care 2010, 33(Suppl 1):S62–69.Google Scholar
  3. 3.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–3421.Google Scholar
  4. 4.
    Krolewski AS, Kosinski EJ, Warram JH, et al.: Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987, 59:750–755.PubMedCrossRefGoogle Scholar
  5. 5.
    Krolewski AS, Warram JH, Valsania P, et al..: Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991, 90:56S–61S.PubMedCrossRefGoogle Scholar
  6. 6.
    Wilson PWF, Kannel W: Epidemiology of hyperglycemia and atherosclerosis. In Hyperglycemia, Diabetes, and Vascular Disease. Edited by Ruderman NWJ, Brownlee M. New York: Oxford; 1992:21–29.Google Scholar
  7. 7.
    Stolar MW: Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism 1988, 37:1–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Assmann G, Schulte H: The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988, 116:1713–1724.PubMedCrossRefGoogle Scholar
  9. 9.
    Abbott RD, Donahue RP, Kannel WB, Wilson PW: The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988, 260:3456–3460.PubMedCrossRefGoogle Scholar
  10. 10.
    Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.PubMedCrossRefGoogle Scholar
  11. 11.
    Moussa I, Leon MB, Baim DS, et al..: Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004, 109:2273–2278.PubMedCrossRefGoogle Scholar
  12. 12.
    Hermiller JB, Raizner A, Cannon L, et al..: Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005, 45:1172–1179.PubMedCrossRefGoogle Scholar
  13. 13.
    Anderson JL, Adams CD, Antman EM, et al..: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007, 116:e148–e304.PubMedCrossRefGoogle Scholar
  14. 14.
    Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) investigators. N Engl J Med 1996, 335:217–225.CrossRefGoogle Scholar
  15. 15.
    Hurst RT, Lee RW: Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med 2003, 139:824–834.PubMedGoogle Scholar
  16. 16.
    Pyðrälä K, Pedersen TR, Kjekshus J, et al..: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614–620.CrossRefGoogle Scholar
  17. 17.
    Matsumoto T, Ohashi Y, Yamada N, Kikuchi M: Coronary heart disease mortality is actually low in diabetic Japanese by direct comparison with the Joslin cohort. Diabetes Care 1994, 17:1062–1063.PubMedCrossRefGoogle Scholar
  18. 18.
    O’Brien T, Nguyen TT, Zimmerman BR: Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998, 73:969–976.PubMedCrossRefGoogle Scholar
  19. 19.
    Taskinen MR, Beltz WF, Harper I, et al..: Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy. Diabetes 1986, 35:1268–1277.PubMedCrossRefGoogle Scholar
  20. 20.
    DCCT Research Group: Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. Diabetes Care 1992, 15:886–894.CrossRefGoogle Scholar
  21. 21.
    Brunzell JD, Davidson M, Furberg CD, et al..: Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811–822.PubMedCrossRefGoogle Scholar
  22. 22.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III): Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.CrossRefGoogle Scholar
  23. 23.
    Kastelein JJ, Akdim F, Stroes ES, et al..: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431–1443.PubMedCrossRefGoogle Scholar
  24. 24.
    DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995, 333:541–549.PubMedCrossRefGoogle Scholar
  25. 25.
    Dunn FL, Pietri A, Raskin P: Plasma lipid and lipoprotein levels with continuous subcutaneous insulin infusion in type I diabetes mellitus. Ann Intern Med 1981, 95:426–431.PubMedGoogle Scholar
  26. 26.
    Manson JE, Nathan DM, Krolewski AS, et al..: A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 1992, 268:63–67.PubMedCrossRefGoogle Scholar
  27. 27.
    Koskinen P, Manttari M, Manninen V, et al..: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820–825.PubMedCrossRefGoogle Scholar
  28. 28.
    The Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.CrossRefGoogle Scholar
  29. 29.
    Barter PJ, Caulfield M, Eriksson M, et al..: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.PubMedCrossRefGoogle Scholar
  30. 30.
    The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977–986.CrossRefGoogle Scholar
  31. 31.
    Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995, 75:894–903.PubMedCrossRefGoogle Scholar
  32. 32.
    Nathan DM, Cleary PA, Backlund JY, et al..: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643–2653.PubMedCrossRefGoogle Scholar
  33. 33.
    Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545–2559.CrossRefGoogle Scholar
  34. 34.
    Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.PubMedCrossRefGoogle Scholar
  35. 35.
    Malmberg K, Ryden L, Efendic S, et al..: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26:57–65.PubMedCrossRefGoogle Scholar
  36. 36.
    UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703–713.Google Scholar
  37. 37.
    Adler AI, Stratton IM, Neil HA, et al..: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412–419.PubMedCrossRefGoogle Scholar
  38. 38.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.CrossRefGoogle Scholar
  39. 39.
    Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.CrossRefGoogle Scholar
  40. 40.
    Jonas M, Reicher-Reiss H, Boyko V, et al..: Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996, 77:1273–1277.PubMedCrossRefGoogle Scholar
  41. 41.
    Schneider DJ, Sobel BE: Effect of diabetes on the coagulation and fibrinolytic systems and its implications for atherogenesis. Coronary Artery Dis 1992, 26–32.CrossRefGoogle Scholar
  42. 42.
    Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81–106.Google Scholar
  43. 43.
    American Diabetes Association: Standards of medical care in diabetes: 2006. Diabetes Care 2006, 29(Suppl 1):S4–S42.Google Scholar
  44. 44.
    Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • David S. Frankel
    • 1
  • Peter W. F. Wilson
    • 2
  • James B. Meigs
    • 3
  1. 1.Department of Medicine, Division of Cardiovascular MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Cardiology DivisionRollins School of Public Health Emory University, Atlanta Veterans Affairs Medical CenterAtlantaUSA
  3. 3.General Medicine Division, Harvard Medical SchoolMassachusetts General HospitalBostonUSA

Personalised recommendations